These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39068669)

  • 1. Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment.
    Janelidze S; Barthélemy NR; Salvadó G; Schindler SE; Palmqvist S; Mattsson-Carlgren N; Braunstein JB; Ovod V; Bollinger JG; He Y; Li Y; Raji CA; Morris JC; Holtzman DM; Ashton NJ; Blennow K; Stomrud E; Bateman RJ; Hansson O
    JAMA Neurol; 2024 Sep; 81(9):947-957. PubMed ID: 39068669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
    Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
    JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
    Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
    Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.
    Mattsson-Carlgren N; Collij LE; Stomrud E; Pichet Binette A; Ossenkoppele R; Smith R; Karlsson L; Lantero-Rodriguez J; Snellman A; Strandberg O; Palmqvist S; Ashton NJ; Blennow K; Janelidze S; Hansson O
    JAMA Neurol; 2024 Jan; 81(1):69-78. PubMed ID: 38048096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
    Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
    JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of Brain Tau Pathology in Down Syndrome Using Plasma Biomarkers.
    Janelidze S; Christian BT; Price J; Laymon C; Schupf N; Klunk WE; Lott I; Silverman W; Rosas HD; Zaman S; Mapstone M; Lai F; Ances BM; Handen BL; Hansson O
    JAMA Neurol; 2022 Aug; 79(8):797-807. PubMed ID: 35789365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology.
    Ashton NJ; Brum WS; Di Molfetta G; Benedet AL; Arslan B; Jonaitis E; Langhough RE; Cody K; Wilson R; Carlsson CM; Vanmechelen E; Montoliu-Gaya L; Lantero-Rodriguez J; Rahmouni N; Tissot C; Stevenson J; Servaes S; Therriault J; Pascoal T; Lleó A; Alcolea D; Fortea J; Rosa-Neto P; Johnson S; Jeromin A; Blennow K; Zetterberg H
    JAMA Neurol; 2024 Mar; 81(3):255-263. PubMed ID: 38252443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.
    Barthélemy NR; Salvadó G; Schindler SE; He Y; Janelidze S; Collij LE; Saef B; Henson RL; Chen CD; Gordon BA; Li Y; La Joie R; Benzinger TLS; Morris JC; Mattsson-Carlgren N; Palmqvist S; Ossenkoppele R; Rabinovici GD; Stomrud E; Bateman RJ; Hansson O
    Nat Med; 2024 Apr; 30(4):1085-1095. PubMed ID: 38382645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.
    Sperling RA; Donohue MC; Rissman RA; Johnson KA; Rentz DM; Grill JD; Heidebrink JL; Jenkins C; Jimenez-Maggiora G; Langford O; Liu A; Raman R; Yaari R; Holdridge KC; Sims JR; Aisen PS
    J Prev Alzheimers Dis; 2024; 11(4):802-813. PubMed ID: 39044488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma p-tau217 predicts cognitive impairments up to ten years before onset in normal older adults.
    Yakoub Y; Gonzalez-Ortiz F; Ashton NJ; Déry C; Strikwerda-Brown C; St-Onge F; Ourry V; Schöll M; Geddes MR; Ducharme S; Montembeault M; Rosa-Neto P; Soucy JP; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
    medRxiv; 2024 May; ():. PubMed ID: 38766113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma p-tau231 and p-tau217 inform on tau tangles aggregation in cognitively impaired individuals.
    Ferreira PCL; Therriault J; Tissot C; Ferrari-Souza JP; Benedet AL; Povala G; Bellaver B; Leffa DT; Brum WS; Lussier FZ; Bezgin G; Servaes S; Vermeiren M; Macedo AC; Cabrera A; Stevenson J; Triana-Baltzer G; Kolb H; Rahmouni N; Klunk WE; Lopez OL; Villemagne VL; Cohen A; Tudorascu DL; Zimmer ER; Karikari TK; Ashton NJ; Zetterberg H; Blennow K; Gauthier S; Rosa-Neto P; Pascoal TA
    Alzheimers Dement; 2023 Oct; 19(10):4463-4474. PubMed ID: 37534889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.
    Janelidze S; Teunissen CE; Zetterberg H; Allué JA; Sarasa L; Eichenlaub U; Bittner T; Ovod V; Verberk IMW; Toba K; Nakamura A; Bateman RJ; Blennow K; Hansson O
    JAMA Neurol; 2021 Nov; 78(11):1375-1382. PubMed ID: 34542571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
    Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
    Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
    Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
    Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
    Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O
    JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
    Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
    JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.
    Bali D; Hansson O; Janelidze S
    Alzheimers Res Ther; 2024 Feb; 16(1):31. PubMed ID: 38331843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.